Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Innovation is in the Air When most of us think about innovative companies, Apple, Google, and Amazon leap to mind. You might be surprised to learn that there are a number of healthcare/life-sciences companies that are also topping the most disruptive and/or innovative lists of several arbiters of such rankings. But what is a disruptive company? According to MIT Technology Review, it is a business whose innovations force other businesses to alter their strategic course. This is similar to the definition put forth by the popular author and business guru Clayton Christensen (see the May 2009 issue of PharmaVOICE). For Mr. Christensen, disruption can be both a threat and an opportunity — it all depends how a company frames it. In general, though, he views disruptive innovation as a huge growth opportunity for the pharmaceutical industry. On MIT Technology Review’s 50 Disruptive Companies in 2012 are: Athenahealth, Cellular Dynamics International, Complete Genomics, Foundation Medicine, Healthpoint Services, Integrated Diagnostics, Life Technologies, Organovo, PatientsLikeMe, and Roche. (www2.technologyreview.com/tr50/2012/). Fast Track Company, which is another great barometer of what’s hot, identified Life Technologies, Siemens AG, Genentech, and Narayana Hrudayalaya Hospitals on its 2012 list of the 50 most innovative companies (www.fastcompany.com/most-innovative-­companies/­2012/­full-list). Among the healthcare companies listed on Forbes’ most innovative companies are: Intuitive Surgical, Hindustan Unilever, Celgene, Alcon, Procter & Gamble, CSL, Thermo Fisher Scientific, Boston Scientific, and Stryker (www.forbes.com/special-features/innovative-companies-list.html). According to Booz Co.’s Global Innovation 1000 study of R&D spending, over the past eight years, there is no long-term correlation between the amount of money a company spends on its innovation efforts and its overall financial performance; instead, what matters is how companies use that money and other resources, as well as the quality of their talent, processes, and decision-making. Those are the things that determine their ability to execute their innovation agendas. The Booz study also found that 43% of participants said their efforts to generate new ideas were highly effective, and only 36% felt the same way about their efforts to convert ideas to product development projects. Altogether, only a quarter of all respondents indicated that their organizations were highly effective at both. The business consultancy Insigniam, which also recently conducted a survey among Global 1000 companies, found that 76% of executives believe that innovation is very important to their ability to succeed and strengthen competitive advantage in the next one to three years. Furthermore, 75% of the executives who rated innovation as very important define innovation as offerings (their product or service offered in the market) or process (their internal processes, procedures, and practices). We want to thank our friends at PwC and EY for their invaluable insights in helping us with our overview of how disruptive innovation is expected to shape the life-sciences industry now and in the future. Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh Managing EDitor Denise Myshko Senior EDitor Robin Robinson features EDitor Kim Ribbink design associate Ariel Medel national account managerS Trish Kane Cathy Tracy WEBCAST?NETWORK?PRODUCER Daniel Limbach CIRCULATION Assistant Kathy Deiuliis Copyright 2013 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Thirteen, Number Three PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O.?Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices. Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. PharmaVoice Coverage and Distribution: Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197. Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com. Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com. Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change. Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O.?Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com. Volume 13 • Number 3 Their Word… Denise Myshko Managing Editor To bring innovative products to the market, companies will have to consider new ­approaches to discovery and ­development. Robin Robinson Senior Editor A new, invigorated focus on patient adherence could be the biggest game changer in ­commercialization since the ­advent of DTC. Kim Ribbink Feature Editor Innovation ­distinguishes between a leader and a follower. — Steve Jobs. The ­life-sciences industry must become a leader if it wants to be successful in the future. Send your letters to feedback@pharma­voice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC. Coming in April 2013 > Empowered Patients aka Super Consumers > Marketing and Regulatory ­Compliance > Nanotechnology Drug Delivery > Counterfeit Drugs > mHealth Guidelines > CEO Corner: CROs > Singapore > Measuring Marketing ROI > Showcase Features — Medical Affairs; Patient Protection: IRBs and Monitoring

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK